Evidence map›Paper›PMID 41827741›Full record

ReviewCancers2026

VEGF-TKI Outcomes in Metastatic Renal Cell Carcinoma According to Prior Immune Checkpoint Inhibitor or VEGF-TKI: A Scoping Review and Exploratory Analysis.

Elizabeth Nally, Agne Jovaisaite, Sara Coca Membribes, Garima Priyadarshini, Catherine Graham, Alan MacDonald, Francesca Jackson-Spence, Bernadett Szabados, Thomas Powles

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Elizabeth NallyBarts Cancer Institute, NIHR Biomedical Research Centre, Queen Mary University of London, London EC1M 6AU, UK.
Agne JovaisaiteBarts Cancer Institute, NIHR Biomedical Research Centre, Queen Mary University of London, London EC1M 6AU, UK.ORCID 0000-0002-7381-8132
Sara Coca MembribesBarts Cancer Institute, NIHR Biomedical Research Centre, Queen Mary University of London, London EC1M 6AU, UK.
Garima PriyadarshiniBarts Cancer Institute, NIHR Biomedical Research Centre, Queen Mary University of London, London EC1M 6AU, UK.
Catherine GrahamBarts Cancer Institute, NIHR Biomedical Research Centre, Queen Mary University of London, London EC1M 6AU, UK.ORCID 0000-0001-5840-847X
Alan MacDonaldBarts Cancer Institute, NIHR Biomedical Research Centre, Queen Mary University of London, London EC1M 6AU, UK.ORCID 0000-0002-7257-6418
Francesca Jackson-SpenceBarts Cancer Institute, NIHR Biomedical Research Centre, Queen Mary University of London, London EC1M 6AU, UK.ORCID 0000-0001-7654-4889
Bernadett SzabadosBarts Cancer Institute, NIHR Biomedical Research Centre, Queen Mary University of London, London EC1M 6AU, UK.ORCID 0000-0002-8786-0032
Thomas PowlesBarts Cancer Institute, NIHR Biomedical Research Centre, Queen Mary University of London, London EC1M 6AU, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

immune checkpoint inhibitorrenal cell carcinomasecond lineVEGF-TKI

Identifiers

PMID41827741
PMCPMC12984518

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.